Evidence map›Paper›PMID 31354422›Full record

ArticleFrontiers in neuroscience2019

Progression and Pathology of Traumatic Optic Neuropathy From Repeated Primary Blast Exposure.

Alexandra Bernardo-Colón, Victoria Vest, Melissa L Cooper, Sarah A Naguib, David J Calkins, Tonia S Rex

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Visual deficits after traumatic brain injury.Histology and histopathology · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Alexandra Bernardo-ColónVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, United States.
Victoria VestVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, United States.
Melissa L CooperDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, United States.
Sarah A NaguibDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, United States.
David J CalkinsVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, United States.
Tonia S RexVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, United States.
Vanderbilt University · USVanderbilt University Medical Center · US

Funding

VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6M
Vanderbilt/Meharry Initiative for Minority Student DvptR25GM062459 · NIGMS · VANDERBILT UNIVERSITY · PI VELEZ EDWARDS, DIGNA R · 2002 to 2020
$10.4M
Role of the Nrf2/ARE pathway in retinal ganglion cells during glaucoma pathogenesis and neuroprotectionR01EY022349 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CALKINS, DAVID J., REX, TONIA S · 2012 to 2021
$3.8M
Mechanisms of Synaptic Remodeling and Neuronal Self-Repair in Aging and GlaucomaR01EY024997 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 2015 to 2026
$3.8M
Stochastic Models of Visual SearchR01EY021833 · NEI · VANDERBILT UNIVERSITY · PI LOGAN, GORDON DENNIS, PALMERI, THOMAS · 2011 to 2023
$3.3M
Effects of modified erythropoietin on cognition and neuropathologyR01NS094595 · NINDS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LIAO, FRANCESCA-FANG, MCDONALD, MICHAEL P · 2016 to 2018
$1.2M
NCRR NIH HHS UL1 RR024975NEI NIH HHS P30 EY008126NEI NIH HHS R01 EY021833NEI NIH HHS R01 EY022349NEI NIH HHS R01 EY024997NIGMS NIH HHS R25 GM062459NINDS NIH HHS R01 NS094595
6 · The paper itself

Abstract

Indirect traumatic optic neuropathy (ITON) is a condition that is often associated with traumatic brain injury and can result in significant vision loss due to degeneration of retinal ganglion cell (RGC) axons at the time of injury or within the ensuing weeks. We used a mouse model of eye-directed air-blast exposure to characterize the histopathology of blast-induced ITON. This injury caused a transient elevation of intraocular pressure with subsequent RGC death and axon degeneration that was similar throughout the length of the optic nerve (ON). Deficits in active anterograde axon transport to the superior colliculus accompanied axon degeneration and first appeared in peripheral representations of the retina. Glial area in the ON increased early after injury and involved a later period of additional expansion. The increase in area involved a transient change in astrocyte organization independent of axon degeneration. While levels of many cytokines and chemokines did not change, IL-1α and IL-1β increased in both the ON and retina. In contrast, glaucoma shows distal to proximal axon degeneration with astrocyte remodeling and increases in many cytokines and chemokines. Further, direct traumatic optic neuropathies have a clear site of injury with rapid, progressive axon degeneration and cell death. These data show that blast-induced ITON is a distinct neuropathology from other optic neuropathies.

Indexed as

axon degenerationaxonopathyblastindirect traumatic optic neuropathyintraocular pressureoptic neuropathyrepeat neurotraumaretinal ganglion cells

Identifiers

PMID31354422
PMCPMC6637732
OpenAlexW2958314917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.